FDA approves a new drug as an alternative to chemotherapy
The US Food and Drug Administration has approved the use of an immunotherapy drug, Pembrolizumab, as a first-line treatment for people with Non-Small Cell Lung Cancer (NSCLC). The drug, which primes the immune system to fight cancer, can be accessed by patients without first having to receive chemotherapy. NSCLC reportedly accounts for up to 90% of all lung cancer patients.